Navigation Links
Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline
Date:10/26/2007

WELLESLEY, Mass., Oct. 26 /PRNewswire-FirstCall/ -- Coley Pharmaceutical Group, Inc. (Nasdaq: COLY), today announced that the company has received a $3.0 million milestone payment from GlaxoSmithKline (GSK) associated with the initiation of GSK's Phase III clinical trial in non-small cell lung cancer (NSCLC) of an immunotherapeutic cancer vaccine containing Coley's VaxImmune(TM) vaccine adjuvant.

In June 2007, GSK announced the launch of the largest Phase III clinical trial in lung cancer to evaluate the MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (MAGE-A3 ASCI) in patients with early stage, completely resected NSCLC. VaxImmune is one of the components of MAGE-A3 ASCI, intended to increase an anti-tumor immune response. The randomized, double-blind, and placebo-controlled Phase III clinical trial, known as the MAGRIT trial (MAGE- A3 as Adjuvant Non-Small Cell Lung Cancer Immunotherapy) will target enrollment of about 2,270 patients with stage IB, II or IIIA resectable NSCLC. The primary endpoint of the trial is disease-free survival. The $3 million development milestone was triggered by the initiation of this Phase III trial.

VaxImmune is Coley's proprietary TLR9 agonist designed to induce both an enhanced antibody response and a potent killer T cell immune response when used in conjunction with vaccines in order to achieve and sustain a clinical response without compromising safety. Coley has granted GSK worldwide licenses for the use of VaxImmune in GSK's vaccines in development for certain cancers and infectious diseases.

About Coley Pharmaceutical Group

Coley Pharmaceutical Group, Inc. is an international biopharmaceutical company, headquartered in Wellesley, Massachusetts, USA, that
'/>"/>

SOURCE Coley Pharmaceutical Group, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 2015  Pomerantz LLP is investigating claims on behalf ... "Company") (NASDAQ: VTAE ).  Such investors are ... rswilloughby@pomlaw.com or 888-476-6529, ext. 237. ... officers and/or directors have violated Sections 10(b) and 20(a) ... On February 27, 2015, the Company announced that ...
(Date:2/27/2015)... Securities lawyers at Dunnam & Dunnam ... (NASDAQ: SLXP ) in connection with a ... are encouraged to contact attorney Hamilton Lindley by ... upon the shareholder value of the transaction. Under terms ... $158.00 per share in cash. At least one analyst ...
(Date:2/27/2015)... LONDON , February 27, 2015 ... - new study showing you trends, R&D progress, and ... medicine heading? What are the commercial prospects for ... shows you potential revenues and other trends to 2025, ... ,s report lets you assess regenerative medicine : ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vitae Pharmaceuticals, Inc. - VTAE 2Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8
... Tolerability and,Additive Antiviral Activity of HCV-796 -, EXTON, ... announced additional data from a Phase 1b study,of ... virus (HCV),polymerase inhibitor at the 42nd Annual Meeting ... Liver (EASL). This meeting is,being held in Barcelona, ...
... Data on Innovative Oncology Compounds at the,American ... PARK, Ill., April 13, 2007 /PRNewswire-FirstCall/ -- ... that target,cancer. Researchers now know that cancer ... new blood vessels to deliver oxygen,and nutrients ...
Cached Medicine Technology:ViroPharma Announces Presentation of Additional HCV-796 Data at,Meeting of The European Association for the Study of the Liver 2ViroPharma Announces Presentation of Additional HCV-796 Data at,Meeting of The European Association for the Study of the Liver 3ViroPharma Announces Presentation of Additional HCV-796 Data at,Meeting of The European Association for the Study of the Liver 4ViroPharma Announces Presentation of Additional HCV-796 Data at,Meeting of The European Association for the Study of the Liver 5ViroPharma Announces Presentation of Additional HCV-796 Data at,Meeting of The European Association for the Study of the Liver 6Abbott Researchers Focus on New Cutting-Edge Approaches in the,Fight Against Cancer 2Abbott Researchers Focus on New Cutting-Edge Approaches in the,Fight Against Cancer 3Abbott Researchers Focus on New Cutting-Edge Approaches in the,Fight Against Cancer 4
(Date:3/2/2015)... Minneapolis, Minnesota (PRWEB) March 02, 2015 ... a new strategic relationship with First Protective Insurance ... new initiative will allow First Protective affiliated advisors ... and implementation support that Secura Consultants delivers. ... is a national leader in the design and ...
(Date:3/1/2015)... Excellence is pleased to announce the addition of a digital ... are over 75 terms and phrases available for viewing, with more ... patients a better understanding of what our Providers are talking about ... With this resource, our patients are able to go back to ... that they may not remember or comprehend at the time of ...
(Date:3/1/2015)... Researchers say working around asbestos-containing construction products may ... contract malignant mesothelioma. Surviving Mesothelioma has just posted the ... Click here to read it now. , Scientists ... 17,345 sheet metal workers from 1986 to 2010 and ... mesothelioma or another asbestos-related disease . , “Significant ...
(Date:3/1/2015)... (PRWEB) March 01, 2015 Indiana ... Network Service Provider, announces NewWays Networking, LLC (NewWays) ... “By working with IFN, NewWays is well positioned ... client’s demand for Internet bandwidth in rural parts ... , According to Cory Childs IFN Enterprise Sales ...
(Date:3/1/2015)... CrossFit Attollo is a CrossFit gym located in Vancouver ... to new members. Now through the end of March ... will receive their fourth month half off. , ... The three month contract is only $264, dropping the price ... comes in at only $55. The special saves new members ...
Breaking Medicine News(10 mins):Health News:Secura Consultants and First Protective Insurance Group Announce Strategic Relationship 2Health News:New Study Finds Indirect Asbestos Exposure Can Raise Mesothelioma Risk for Sheet Metal Workers, According to Surviving Mesothelioma 2Health News:NewWays Networking Selects Indiana Fiber Network, LLC as Fiber Transport Provider 2Health News:CrossFit Gym in Vancouver WA Offers Spring Special 2
... "As a physician,you hear all sorts of excuses ... Hashey, Medical Director of First Coast Family Medicine and ... most common that Dr. Hashey reports is the excuse ... "That couldn,t be farther from the truth.,The flu shot ...
... for ... Cardiac Rehabilitation, BOTHELL, Wash., ... global leader in advanced cardiac monitoring,and defibrillation products, announced today ... has seamless connectivity with LUMEDX,CardioWellness(TM) data management software. (Logo: ...
... patient outcomes at Houston Northwest Medical ... among nation,s best for several service lines, ... Annual,HealthGrades Hospital Quality in America Study issued today, ... several service,lines including overall gastrointestinal services, gastrointestinal,surgery, stroke, ...
... Oct. 17 /PRNewswire/ - The numbers are staggering --,over ... have a,disability. "It,s not the impairment or disability ... their exclusion from mainstream,social, economic and political opportunities," says ... have to work together to stand up and speak ...
... methicillin-resistant Staphylococcus aureus Infections in the, United States, shows that hospital-caused MRSA ... and Prevention have,consistently understated the size of the problem and have failed ... protect patients from these ... infections., NEW ...
... hold a press availability tomorrow, Wednesday, October 17, at 10:30,a.m. ... 2-year-old,from Tampa, Fla., who was born with a serious heart ... is on Capitol Hill urging Members of,Congress to vote to ... 10 million children., WHO: Speaker Nancy ...
Cached Medicine News:Health News:Flu Myths Abound in Flu Season 2Health News:Cardiac Science Announces Data Connectivity with LUMEDX 2Health News:Cardiac Science Announces Data Connectivity with LUMEDX 3Health News:Cardiac Science Announces Data Connectivity with LUMEDX 4Health News:Houston Northwest Medical Center's Patient Outcomes Superior 2Health News:Houston Northwest Medical Center's Patient Outcomes Superior 3Health News:CBM USA stands up and speaks out to world leaders on the International Day for the Eradication of Poverty 2Health News:The Journal of the American Medical Association (JAMA) Article Reveals Scope of MRSA Infections 2
For injecting viscoelastic to all meridians of the anterior chamber and to coat intraocular lenses. 20G x 7.8in (.90 x 22mm)....
For administering anesthetic agents into the posterior sub-Tenon's space 20G x 1in (.90 x 25mm)...
... most versatile diagnostic tool in the eye ... glaucoma, diabetic retinopathy, age-related macular degeneration and ... the only system in the market that ... the optic nerve areas in one session, ...
Stryker Leibinger offers a variety of different Titanium Implant Systems and special instrument sets, which enable our customers to treat a wide range of indication...
Medicine Products: